Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design
Am J Respir Crit Care Med
.
2012 Sep 1;186(5):464.
doi: 10.1164/ajrccm.186.5.464.
Authors
John L Johnson
,
Bonnie A Thiel
PMID:
22942350
PMCID:
PMC3443806
DOI:
10.1164/ajrccm.186.5.464
No abstract available
Publication types
Letter
MeSH terms
Antitubercular Agents / therapeutic use*
Clinical Trials, Phase III as Topic / methods*
Follow-Up Studies
Humans
Recurrence
Time Factors
Treatment Outcome
Tuberculosis / drug therapy*
Substances
Antitubercular Agents
Grants and funding
N01AI70022/AI/NIAID NIH HHS/United States
N01AI95383/AI/NIAID NIH HHS/United States